JP7194595B2 - グランザイムｂを指向するイメージングおよび治療 - Google Patents

グランザイムｂを指向するイメージングおよび治療 Download PDF

Info

Publication number
JP7194595B2
JP7194595B2 JP2018568685A JP2018568685A JP7194595B2 JP 7194595 B2 JP7194595 B2 JP 7194595B2 JP 2018568685 A JP2018568685 A JP 2018568685A JP 2018568685 A JP2018568685 A JP 2018568685A JP 7194595 B2 JP7194595 B2 JP 7194595B2
Authority
JP
Japan
Prior art keywords
group
granzyme
imaging
seq
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525910A5 (cg-RX-API-DMAC7.html
JP2019525910A (ja
Inventor
マフムード，ウマー
ラリマー，ベンジャミン
ウェレンバーグ－クレー，エリック
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2019525910A publication Critical patent/JP2019525910A/ja
Publication of JP2019525910A5 publication Critical patent/JP2019525910A5/ja
Priority to JP2022143354A priority Critical patent/JP2023002508A/ja
Application granted granted Critical
Publication of JP7194595B2 publication Critical patent/JP7194595B2/ja
Priority to JP2025014429A priority patent/JP2025081347A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/40—Animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018568685A 2016-07-01 2017-06-30 グランザイムｂを指向するイメージングおよび治療 Active JP7194595B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022143354A JP2023002508A (ja) 2016-07-01 2022-09-09 グランザイムｂを指向するイメージングおよび治療
JP2025014429A JP2025081347A (ja) 2016-07-01 2025-01-31 グランザイムｂを指向するイメージングおよび治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662357845P 2016-07-01 2016-07-01
US62/357,845 2016-07-01
US201662435541P 2016-12-16 2016-12-16
US62/435,541 2016-12-16
PCT/US2017/040212 WO2018005926A1 (en) 2016-07-01 2017-06-30 Granzyme b directed imaging and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143354A Division JP2023002508A (ja) 2016-07-01 2022-09-09 グランザイムｂを指向するイメージングおよび治療

Publications (3)

Publication Number Publication Date
JP2019525910A JP2019525910A (ja) 2019-09-12
JP2019525910A5 JP2019525910A5 (cg-RX-API-DMAC7.html) 2020-08-06
JP7194595B2 true JP7194595B2 (ja) 2022-12-22

Family

ID=60787787

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018568685A Active JP7194595B2 (ja) 2016-07-01 2017-06-30 グランザイムｂを指向するイメージングおよび治療
JP2022143354A Pending JP2023002508A (ja) 2016-07-01 2022-09-09 グランザイムｂを指向するイメージングおよび治療
JP2025014429A Pending JP2025081347A (ja) 2016-07-01 2025-01-31 グランザイムｂを指向するイメージングおよび治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022143354A Pending JP2023002508A (ja) 2016-07-01 2022-09-09 グランザイムｂを指向するイメージングおよび治療
JP2025014429A Pending JP2025081347A (ja) 2016-07-01 2025-01-31 グランザイムｂを指向するイメージングおよび治療

Country Status (4)

Country Link
US (2) US11559590B2 (cg-RX-API-DMAC7.html)
EP (1) EP3478162B1 (cg-RX-API-DMAC7.html)
JP (3) JP7194595B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018005926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241511B2 (en) * 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
US11667645B2 (en) 2018-02-13 2023-06-06 Cytosite Biopharma Inc. Granzyme B directed imaging and therapy
WO2021252664A1 (en) * 2020-06-09 2021-12-16 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
CN114075263B (zh) * 2020-08-18 2023-09-19 中南大学湘雅三医院 一种近红外分子探针及其制备和在检测颗粒酶b中的应用
CN113512090A (zh) * 2021-04-30 2021-10-19 复旦大学附属肿瘤医院 一种颗粒酶b结合化合物及其前体化合物和用途
CN114028590B (zh) * 2021-11-18 2022-09-06 北京大学 颗粒酶b靶向配合物、放射性药物及其制备方法和应用
JP2025501465A (ja) * 2021-12-08 2025-01-22 サイトサイト バイオファーマ インコーポレイテッド グランザイムｂに特異的な化合物及びその使用
JP2024546710A (ja) * 2021-12-08 2024-12-26 サイトサイト バイオファーマ インコーポレイテッド グランザイムｂに特異的な化合物のためのプロドラッグ及びその使用
JPWO2024143314A1 (cg-RX-API-DMAC7.html) * 2022-12-27 2024-07-04
CN116589527B (zh) * 2023-04-25 2023-12-12 北京大学第一医院 一种颗粒酶b靶向抑制剂及核医学探针与应用
WO2024228936A1 (en) * 2023-05-03 2024-11-07 Merck Sharp & Dohme Llc Cyclic peptides as pet imaging agents of granzyme b
TW202508601A (zh) * 2023-06-07 2025-03-01 美商塞托賽特生物製藥股份有限公司 對顆粒酶ｂ具有特異性之化合物之前驅藥及其用途
WO2025226524A1 (en) * 2024-04-23 2025-10-30 Merck Sharp & Dohme Llc Granzyme b pet imaging agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184493A1 (en) 2002-01-29 2007-08-09 Oncoimmunin Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
JP2012513591A (ja) 2008-12-22 2012-06-14 ザ チルドレンズ リサーチ インスティテュート 敗血症の検出のための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
WO2003065987A2 (en) 2002-02-04 2003-08-14 Merck & Co., Inc. Granzyme b inhibitors
ATE457349T1 (de) 2002-08-23 2010-02-15 Multhoff Gabriele Prof Dr Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
WO2005117928A1 (en) 2004-05-30 2005-12-15 Cemines, Inc. Compositions and methods for the treatment of skin cancer
US20080311036A1 (en) 2005-05-11 2008-12-18 University Of Florida Research Foundation, Inc. Imaging of Neural and Organ Injury or Damage
JP2009509979A (ja) 2005-09-29 2009-03-12 ユニバーシティ オブ アルバータ グランザイムｂ阻害のための組成物および方法
CA2739512A1 (en) 2007-10-01 2009-04-09 The University Of British Columbia Granzyme a and granzyme b diagnostics
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
US9290794B2 (en) * 2010-05-11 2016-03-22 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
NZ612533A (en) * 2010-12-06 2015-03-27 Univ British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
CA2908315A1 (en) * 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Cosmetic uses and methods for indoline granzyme b inhibitor compositions
KR101552943B1 (ko) 2013-03-29 2015-09-14 한양대학교 산학협력단 형광공명에너지전이 현상을 이용한 면역반응 영상화
DK3417058T3 (da) * 2016-02-16 2021-11-15 Res Found Dev Sortase-modificerede molekyler og anvendelser deraf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184493A1 (en) 2002-01-29 2007-08-09 Oncoimmunin Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
JP2012513591A (ja) 2008-12-22 2012-06-14 ザ チルドレンズ リサーチ インスティテュート 敗血症の検出のための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Circ. Res. (2015) vol.117, issue 6, p.502-512

Also Published As

Publication number Publication date
EP3478162A4 (en) 2020-07-29
US12246075B2 (en) 2025-03-11
EP3478162A1 (en) 2019-05-08
JP2025081347A (ja) 2025-05-27
US20230338588A1 (en) 2023-10-26
US20190224348A1 (en) 2019-07-25
US11559590B2 (en) 2023-01-24
JP2019525910A (ja) 2019-09-12
WO2018005926A1 (en) 2018-01-04
JP2023002508A (ja) 2023-01-10
EP3478162B1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
JP7194595B2 (ja) グランザイムｂを指向するイメージングおよび治療
CN102369218B (zh) 抗-FcRH5抗体和免疫缀合物以及应用方法
CN102471380B (zh) 抗FcRH5抗体和免疫偶联物及使用方法
JP7414370B2 (ja) 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体
TW201602134A (zh) 抗-ｃｄ７９ｂ抗體及免疫共軛物及使用方法
JP2022527398A (ja) ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法
US20240165278A1 (en) Granzyme b directed imaging and therapy
CN113164632A (zh) 放射性免疫缀合物与检查点抑制剂组合疗法
TW201534305A (zh) 使用組合療法治療癌症之方法
US20230257388A1 (en) Granzyme b directed imaging and therapy
JP2023507385A (ja) 効率の高いミエロペルオキシダーゼ活性化可能な造影剤
WO2017026502A1 (ja) 抗ポドプラニン抗体及び抗体薬物複合体
JP2025501465A (ja) グランザイムｂに特異的な化合物及びその使用
EP3924354A1 (en) Granzyme b directed imaging and therapy
JP2025524915A (ja) グランザイムｂを標的とするセラノスティクス化合物
WO2023108031A1 (en) Prodrugs for compounds specific to granzyme b and uses thereof
WO2018226971A1 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
WO2024254417A2 (en) Compounds specific to granzyme b and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221026

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221212

R150 Certificate of patent or registration of utility model

Ref document number: 7194595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250